Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Maximizing survival in metastatic Castration-Resistant Prostate Cancer: panel discussion

17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress (ECC 2013)

Sorry, this item is currently unavailable.

Published: 10 Jan 2014

Views: 3757

Rating:

Save

J.M. Fitzpatrick, N. Mottet, R. de Wit, Rotterdam and A Birtle

The faculty answers to the questions of the audience.

Chairman conclusion with the take home messages.

Content taken from a Sanofi sponsored satellite symposium at ESMO 2013 as part of the official programme.

Related Videos

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO GU 2023: CRPC updates

Dr Neal Shore, Dr Elena Castro, Prof Gerhardt Attard and Prof Eleni Efstathiou

ASCO GU 2023: CRPC updates ( Dr Neal Shore, Dr Elena Castro, Prof Gerhardt Attard and Prof Eleni Efstathiou )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

Latest in hormone sensitive prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Prof Gerhardt Attard and Prof...

Latest in hormone sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Prof Gerhardt Attard and Prof Heather Payne )

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib...

Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC ( Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

More from ecancer